Cytophage Technologies (TSXV:CYTO) Pre-Tax Income : C$-1.90 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cytophage Technologies's pretax income for the three months ended in Mar. 2024 was C$-4.28 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.90 Mil. Cytophage Technologies's pretax margin was %.

Cytophage Technologies Pre-Tax Income Historical Data

The historical data trend for Cytophage Technologies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Pre-Tax Income Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Pre-Tax Income

-3.24

-0.71

0.02

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial			2.13	-1.16	-0.98	3.36	-4.28

Competitive Comparison of Cytophage Technologies's Pre-Tax Income

For the Biotechnology subindustry, Cytophage Technologies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Pre-Tax Income falls into.

Cytophage Technologies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cytophage Technologies's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.136	+	-0.083	+	0	+	0.241	+	3.4694469519536E-17
	=	0.02

Cytophage Technologies's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.608	+	-2.693	+	-0.027	+	0.043	+	0.0010000000000003
	=	-4.28

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.90 Mil.

Cytophage Technologies (TSXV:CYTO) Pre-Tax Income Explanation

Cytophage Technologies's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-4.284	/	0
	=	%

Cytophage Technologies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.